Sanofi Pasteur, a Sanofi Company
PCV21
Pneumococcal Infections
Countdown
147days
Phase 3 readout · Dec 1, 2026
What's at stake
Phase 3 trial results for PCV21 in Pneumococcal Infections are due Dec 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 14h ago
“CT.gov NCT06838000: Phase 3 trial, sponsor Sanofi Pasteur, a Sanofi Company, drug PCV21. Primary completion date 2026-12-01 (estimated).”